4
The Refractive
Ocular Surface
Key Findings:
Overall, there is little consensus
on diagnostic and treatment
decisions for all severity types
of dry eye and MGD patients.
18% of ophthalmologists see 51 or
more patients a month with ocular
surface disease requiring treatment
beyond artificial tears.
When asked about the Delphi/
DEWS guidelines for treating
aqueous deficient dry eye and MGD,
35% reported they do not know
what the guidelines say, and 38%
think they are following them but are
not certain. International physicians
are more than twice as likely to regu-
larly consult and adhere closely to
the Delphi/DEWS guidelines.
ASCRS members stated that 20% of
all cataract and refractive patients
present with sufficient ocular surface
dysfunction to require advanced
treatment therapies.
An additional 20% present as
asymptomatic but develop
symptoms postoperatively.
"
I use all the available tools to
assist me in diagnosing the type
of dry eye disease I am dealing
with, and then I am tailoring my
treatments accordingly. This is
an exciting and dynamic space,
especially with all the innovative
technology that has now become
available to us. As the chair of the
Cornea Clinical Committee, I am
committed to helping ASCRS physi-
cians develop the right guidance
for their patients, increase patient
satisfaction, and achieve optimal
results starting with the refractive
ocular surface.
"
–Terry Kim, MD,
chair, Cornea Clinical Committee
